Pfizer signs diabetes and obesity R&D deal with Calif. institute

The Sanford-Burnham Medical Research Institute and Pfizer agreed to collaborate in the discovery of new therapeutic targets for drugs that could treat and prevent complications related to diabetes and obesity. As part of the three-year deal, researchers will use Sanford-Burnham's systems biology expertise and screening technologies to identify strategies to address insulin resistance.

View Full Article in:

GenomeWeb Daily News (free registration) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA